A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

GEn1E Lifesciences

Status and phase: Enrolling; Phase 2

Conditions: Respiratory Distress Syndrome, Acute

Treatments: Drug: Placebo; Drug: GEn-1124

Study type: Interventional

Funder types: Industry

Identifiers

NCT05795465

GEn-1124-002

Details and patient eligibility

About

GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.

Full description

Randomized , double-blind, placebo controlled, dose escalation study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of GEn1124.

GEn-1124 or placebo will be administered as a 2-hour IV infusion as early as possible after ARDS diagnosis. Participants will receive a second dose approximately 8 hours after the first and will continue BID for the remaining schedule (Days 2-5). Follow-up will be for a total of 60 days after the first dose or death (whichever comes first).

An independent Safety Review Committee (SRC) will be responsible for reviewing data throughout the study.

Enrollment: 52 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female subject between the ages of 18 and 80 years old, inclusive.
2. Written informed consent .
3. Hospital admission.
4. Dosing as early as possible after first meeting ARDS 2023 Global definition.
5. Acceptable method of birth control.

Exclusion criteria

1. Subject, surrogate, or physician not committed, or eligible, to receive full supportive care measures.
2. Pregnant or breastfeeding
3. Currently incarcerated in a correctional institution or involuntarily committed to an inpatient mental health facility.
4. Active malignancy (other than non-melanoma skin cancer) requiring treatment within the last 3 months or within the last 6 months if an anti-B cell antibody was received.
5. Any other irreversible disease or condition for which 6-month mortality is estimated to be >50%.
6. Moderate to severe liver failure.
7. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 or requiring dialysis prior to hospitalization.
8. Acute Left ventricular failure or congestive heart failure, defined as New York Heart Association Class IV.
9. Severe chronic respiratory disease with continuous home oxygen >2 liters per minute (LPM) or >28% (adjusted for altitude); and/or home noninvasive ventilation (except for the treatment of obstructive sleep apnea).
10. Poly-traumatic injury resulting in significant blood loss and/or likely to require major surgery within the study period, or subject condition that would interfere with study procedures.
11. History of any type of solid organ or cellular transplant.
12. Receiving immunosuppressive therapy for solid organ or hematopoietic cancer, transplant anti-rejection medication, and/or other chronic conditions.
13. Moribund subject not expected to survive 24 hours.
14. Do not resuscitate (DNR) status.
15. World Health Organization (WHO) functional class III or IV pulmonary hypertension.
16. Burn victims currently undergoing treatment for >20% total body surface area (TBSA) involvement or for known airway inhalation injury.
17. Neuromuscular disease that could impact ability to wean from mechanical ventilation.
18. History of tuberculosis (TB); undergoing treatment for latent TB infection (LTBI); untreated LTBI (as determined by documented results within 3 months of Screening of a positive TB test).
19. Active Hepatitis B, positive Hepatitis C (and has not completed antiviral treatment), or positive human immunodeficiency (HIV) screen.
20. Use of any investigational drug or device within last 30 days of dosing or 5 half-lives, whichever is longer.
21. Any other medical, psychiatric, or social condition that, in the opinion of the investigator, is likely to unfavorably alter the risk-benefit of subject participation, to interfere with protocol compliance, or to confound safety.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

52 participants in 4 patient groups, including a placebo group

Part 1 Cohort 1: GEn-1124

Experimental group

Description:

Subjects in cohort 1 will receive low dose GEn-1124 BID intravenous 5 days.

Treatment:

Drug: GEn-1124

Part 1 Cohort 2: GEn-1124

Experimental group

Description:

Subjects in cohort 2 will receive high dose GEn-1124 BID intravenous for 5 days.

Treatment:

Drug: GEn-1124

Placebo

Placebo Comparator group

Description:

Subjects randomized to placebo will receive a placebo in a matching dosing regimen (Placebo BID intravenous for 5 days).

Treatment:

Drug: Placebo

Part 2: GEn-1124

Experimental group

Description:

Depending on the analysis of part 1, subjects in part 2 will receive GEn-1124 BID intravenous for 5 days.

Treatment:

Drug: GEn-1124